JAK2 and myeloproliferative neoplasm: The previously-identified MPN driver mutations were confirmed by NGS on PMF patients’ HSPCs in all cases, except for one out of the six JAK2-mutated patients and for the two CALR-mutated patients, who presented CALR mutation under the detection limit (Figure 3A, Supplementary Table S2).